This review assessed topical non-steroidal anti-inflammatory drugs (NSAIDs) for pain relief for traumatic corneal abrasions. The authors concluded that topical NSAIDs can provide effective analgesia for patients with traumatic corneal abrasions. This was a good-quality systematic review and the conclusions are likely to be reliable.
Assessment of study quality
The studies were assessed for validity using the Jadad scale. Studies that achieved a score of 3 or 4 were described as high quality.
Two reviewers independently assessed the validity of the included studies. No attempt was made to blind the reviewers to the authors, journal or results of the trials.
Data extraction
Two reviewers independently extracted the data from the included studies onto a standardised and piloted data collection form. Any disagreements were resolved by discussion until agreement was reached. Efforts were made to contact the authors of the included studies to confirm the reported findings and to determine any unreported details. Pain scales were standardised to a 0 to 10 scale, converting scores where necessary.
Methods of synthesis
How were the studies combined? Trials that reported adequate data and were homogeneous in terms of the population, design and outcome were pooled using a random-effects model. The overall weighted mean difference and 95% confidence interval (CI) were calculated. The authors intended to assess publication bias using a funnel plot but too few studies reported adequate data.
How were differences between studies investigated?
Statistical heterogeneity was assessed using the Q statistic. Sensitivity analyses were planned to test the impact of the following variables: type of pain scale, trial quality, type of control, language, country of origin, type of topical NSAID, and any other sources of clinical or methodological heterogeneity.
Results of the review
Eleven RCTs were included in the review; the total number of participants was not reported. Sample sizes in the included studies ranged from 22 to 347. Only 5 studies were included in the meta-analysis.
Five trials were high quality. Nine trials did not report methods of randomisation. Four trials were not double-blinded; four described themselves as double-blinded but did not report methods of blinding. Six trials did not report withdrawals or losses to follow-up for each group; 2 trials had large losses to follow-up. None of the trials reported that their methods of allocation were concealed, however, two authors responded to correspondence and indicated that their method of allocation was concealed.
Pain scale score at 24 hours.
Five of the 11 included RCTs reported adequate data to be pooled (three of which were high quality). Three used verbal pain scales and two used a VAS. The standardised mean difference suggested a statistically significant reduction in pain favouring treatment with topical NSAIDs (-0.52, 95% CI: -0.91, -0.13).
When only the 3 high-quality trials were pooled (n=299), the standardised mean difference was -0.22 (95% CI: -0.45, 0.00).
When the 3 RCTs (n=459) that used verbal pain scales were pooled, the overall weighted mean difference suggested a statistically significant reduction in pain favouring treatment with topical NSAIDs (-1.30, 95% CI: -1.56, -1.03, P<0.00001). There was no evidence of significant heterogeneity (Q=1.57, P=0.46). Sensitivity analyses for placebo-controlled trials, language and country of origin did not change the statistical significance of the overall estimate.
Adverse events.
Eight RCTs reported data on adverse events. There were insufficient data to conduct a formal meta-analysis. Two trials
